Particle.news
Download on the App Store
3 ARTICLES
·
2w ago

Meta-Analysis Confirms Nirsevimab’s Real-World Effectiveness Against Severe RSV in Infants

A 27-study review shows the monoclonal antibody significantly reduces RSV-related hospitalizations, ICU admissions, and respiratory infections while highlighting variability across age groups and regions.

Image
Image

Overview

  • Nirsevimab reduces RSV-related hospitalizations by 83%, ICU admissions by 81%, and lower respiratory tract infections by 75%, according to a meta-analysis published in *The Lancet Child & Adolescent Health*.
  • The analysis, encompassing 27 studies from the 2023–2024 RSV season across five countries, validates the antibody's effectiveness in real-world settings.
  • Effectiveness is higher in infants older than 3 months (81%) compared to those 3 months or younger (76%), with regional variation observed.
  • The U.S. reported the highest effectiveness (93%), attributed in part to prioritizing high-risk infants during initial rollout, while France and Spain saw lower rates at 76% and 83%, respectively.
  • Researchers caution that observational study designs may introduce biases related to socioeconomic, health, or regional factors, underscoring the need for further investigation.